Based on this background, we conducted a clinicopathological study to evaluate the prognostic impact of VEGF‐ligand and VEGFR‐receptor expression after osimertinib treatment in patients with advanced or metastatic EGFR‐mutated NSCLC, using Ki‐67 as a tumor cell proliferation marker and system alanine–serine–cysteine amino acid transporter‐2 (ASCT2) as amino acid transporter. This evidence concerns the gene EGFR and neoplasm.